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Objectives The purpose of this study was describe the cardiovascular phenotype of the aneurysms-osteoarthritis syndrome
(AOS) and to provide clinical recommendations.
Background AOS, caused by pathogenic SMAD3 variants, is a recently described autosomal dominant syndrome character-
ized by aneurysms and arterial tortuosity in combination with osteoarthritis.
Methods AOS patients in participating centers underwent extensive cardiovascular evaluation, including imaging, arterial
stiffness measurements, and biochemical studies.
Results We included 44 AOS patients from 7 families with pathogenic SMAD3 variants (mean age: 42  17 years). In
71%, an aortic root aneurysm was found. In 33%, aneurysms in other arteries in the thorax and abdomen were
diagnosed, and in 48%, arterial tortuosity was diagnosed. In 16 patients, cerebrovascular imaging was per-
formed, and cerebrovascular abnormalities were detected in 56% of them. Fifteen deaths occurred at a mean
age of 54  15 years. The main cause of death was aortic dissection (9 of 15; 60%), which occurred at mildly
increased aortic diameters (range: 40 to 63 mm). Furthermore, cardiac abnormalities were diagnosed, such as con-
genital heart defects (6%), mitral valve abnormalities (51%), left ventricular hypertrophy (19%), and atrial fibrillation
(22%). N-terminal brain natriuretic peptide (NT-proBNP) was significantly higher in AOS patients compared with
matched controls (p  0.001). Aortic pulse wave velocity was high-normal (9.2  2.2 m/s), indicating increased aor-
tic stiffness, which strongly correlated with NT-proBNP (r  0.731, p  0.005).
Conclusions AOS predisposes patients to aggressive and widespread cardiovascular disease and is associated with high mor-
tality. Dissections can occur at relatively mildly increased aortic diameters; therefore, early elective repair of the
ascending aorta should be considered. Moreover, cerebrovascular abnormalities were encountered in most
patients. (J Am Coll Cardiol 2012;60:397–403) © 2012 by the American College of Cardiology Foundation
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Aneurysms-Osteoarthritis Syndrome July 31, 2012:397–403Aortic aneurysms and dissections
were ranked as the nineteenth
most common cause of death in
the United States in 2007 (1). The
true incidence is probably much
higher, because many aortic aneu-
rysms are silent. Thoracic aortic an-
eurysms and dissections (TAADs)
See page 404
often are found in the context of
genetic syndromes, such as Marfan
syndrome (MFS) and Loeys-Dietz
syndrome (LDS), but also are asso-
ciated with bicuspid aortic valves
(2–4). MFS is one of the most
common hereditable connective tis-
sue disorders, with abnormalities
predominantly in the skeletal,
ocular, pulmonary, and cardiovas-
cular systems (2). LDS shows some
imilarities with MFS, but exhibits widespread arterial
neurysms and tortuosity (3).
Recently, our group found that pathogenic SMAD3
ariants cause aneurysms-osteoarthritis syndrome (AOS)
5). AOS is inherited as an autosomal dominant disorder
nd is found to be responsible for 2% of familial TAADs
5,6). Aneurysms, dissections, and tortuosity throughout the
rterial tree are the main cardiovascular features (5). In
ddition, early-onset osteoarthritis is present in almost all
atients and often is the first reason to seek medical advice
5). Mild craniofacial abnormalities, such as hypertelorism
nd bifid uvula, also are associated with AOS (5). Further-
ore, umbilical or inguinal hernias, or both; varices; velvety
kin; and striae are common findings (5). The purpose of
his study was to describe the cardiovascular consequences
f AOS and to provide clinical recommendations.
ethods
rom 2009 onward, all AOS patients with a pathogenic
MAD3 variant in participating centers were included in
his ongoing cohort study. Genetic identification methods
ave been described previously (5). Patients underwent
omprehensive clinical evaluation, including risk factor as-
essment, physical examination, biochemical measurements,
2-lead electrocardiography, transthoracic echocardiogra-
hy (TTE), and computed tomography angiography (CTA)
f the thorax and abdomen. For logistical reasons, not all
xaminations could be performed in every patient. In a
ubset of patients, CTA of the cerebral vessels and arterial
tiffness measurements also were performed. These methods
re described extensively in the Online Appendix. Patients
ere monitored for occurrence of cardiovascular events,
Abbreviations
and Acronyms
AF  atrial fibrillation
AOS  aneurysms-
osteoarthritis syndrome
aPWV  aortic pulse
wave velocity
CTA  computed
tomography angiography
LDS  Loeys-Dietz
syndrome
MFS  Marfan syndrome
NT-proBNP  N-terminal
brain natriuretic peptide
TAAD  thoracic aortic
aneurysms and dissections
TGF  transforming growth
factor
TTE  transthoracic
echocardiographyspecially dissection or mortality. Autopsy was requested inase of death and was performed when possible. Biochem-
cal and arterial stiffness measurements were compared
-to-1 with age-, sex-, and smoking status-matched con-
rols. Apparently healthy controls were recruited among
ospital personnel and their acquaintances and underwent
nly biochemical and arterial stiffness measurements and
moking status assessment. The study was approved by the
nstitutional Review Board and Ethical Committee of the
rasmus Medical Center in Rotterdam. Written informed
onsent was obtained from each patient.
ata analysis. SPSS software version 15.0 (SPSS, Inc.,
hicago, Illinois) was used for the statistical analyses. A
value of0.05 was considered statistically significant. The
-sample Kolmogorov-Smirnov test and histograms were
sed to check normality. Normally distributed continuous
ata are presented as mean  SD, and categorical variables
re presented as frequency (n) and percentages. Non-normal
istributed data are presented as median with interquartile
ange (25th and 75th percentiles). For comparison between
he control and patient groups, a Student t test taking into
ccount the 1-to-1 pairing or the signed-rank Wilcoxon test
as used. Biochemical measurements also were compared
ith reference values from the clinical chemical laboratory
f the Erasmus Medical Center in Rotterdam. For correla-
ion analysis, the Pearson r correlation coefficient and
pearman correlation test were used.
esults
e here describe the cardiovascular features of 44 AOS
atients from 7 families. Genetic mutations are specified in
nline Table 1. Twenty-seven patients from 3 families were
escribed previously in brief in the first report on AOS (5).
able 1 presents the baseline characteristics of the study
opulation. Two patients (62 and 64 years of age) had
ypertension and used antihypertensive drugs.
Baseline CharacteristicsTable 1 Baseline Characteristics
Covariates AOS Patients (n  44)
Age, yrs 42 17
Male 24 (55)
Height, cm 181 13
Weight, kg 78 15
Body mass index, kg/m2 24 4
Blood pressure, mm Hg
Systolic blood pressure 124 14
Diastolic blood pressure 74 8
Mean arterial pressure 92 11
Oxygen saturation, % 98 1
Smoking*
Never 24 (73)
Current 6 (18)
Former 3 (9)
Creatinine, mol/l* 72 11
Values are mean SD or n (%). *Smoking status and creatinine measurements could be obtained
from only 33 patients.
AOS  aneurysms-osteoarthritis syndrome.
pO
b
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July 31, 2012:397–403 Aneurysms-Osteoarthritis SyndromeSurvival. Fifteen deaths in AOS patients with confirmed
athogenic SMAD3 variants occurred at a mean age of 54
15 years. Autopsy confirmed an aortic dissection as cause of
death in 6 patients. In the 9 other patients, no autopsy was
performed, but 3 patients were known previously to have
aortic aneurysms or dissections. Causes of death with age at
time of death are specified in Online Table 1. No intracra-
nial hemorrhage as the cause of death has been reported.
Aneurysms, dissections, and arterial tortuosity in the
thorax and abdomen. In 27 (71%) of 38 patients, an aortic
root aneurysm was found (range: 36 to 63 mm, z-score: 2.9
to 13.2) (Fig. 1A, Online Video 1, Online Figs. 1 and 2).
For 6 patients, we did not have aortic dimension data
because they died before TTE or CTA could be performed.
In 8 (33%) of 24 patients, aneurysms in other arteries in the
thorax and abdomen were diagnosed: descending thoracic
and abdominal aorta (100 mm), pulmonary trunk (50 mm),
superior mesenteric, splenic (40 mm), celiac, hepatic, and
common, external and internal iliac arteries (80 mm)
(Fig. 1B, detailed information in Online Table 1, Online
Figs. 3 and 4). Arterial tortuosity throughout the great
Figure 1 Cardiovascular Abnormalities throughout the Body in
(A) Thorax: (left) aneurysm of the aortic root (54 mm) in 31-year-old man, and (m
40 mm in a 50-year-old woman. (B) Abdomen: (left) aortic dissection at a maxima
mon iliac artery (true lumen in internal iliac artery and false lumen in external iliac
artery (16 mm) in 45-year-old woman; (middle and right) tortuosity and aneurysm
(left) 2 saccular aneurysms in the left and right carotid siphon in a 31-year-old ma
and (right) tortuosity of the internal carotid artery in a 34-year-old man. Also see Ovessels of the abdomen and thorax was present in 48% (11
of 23) (Online Video 2).
Mean aortic diameters measured by CTA and TTE are
shown in Table 2. The aorta was dilated most often at the
level of the sinus of Valsalva. CTA aortic diameter mea-
surements correlated well with TTE (sinus of Valsalva: r 
0.939, p  0.001). Two (33%) of 6 evaluated children had
aortic diameter z-scores that were higher than the normal
range according to age (z  2.9 in a 16-year-old boy and
z  3.3 in a 15-year-old girl).
Thirteen patients with a mean age of 46  10 years were
diagnosed with 1 or more aortic dissections. Stanford type A
aortic dissection was diagnosed in 11 patients (Fig. 1A,
Online Fig. 2). In 8 patients, this was the first manifestation
of the disease. Range of sinus of Valsalva diameter measured
before aortic root dissection occurred was 40 to 63 mm
(reliable aortic measurements before dissection were avail-
able only for 5 patients). Stanford type B aortic dissection
was diagnosed in 2 patients (Fig. 1B, Online Video 3,
nline Fig. 3). In addition, 2 patients were diagnosed with
oth a type A and B dissection at different time points.
nts with Aneurysms-Osteoarthritis Syndrome
nd right) Stanford type A aortic dissection at a maximal aortic diameter of
minal aortic diameter of 24 mm with dissection flap extending into the left com-
) and aneurysm in the right common iliac artery (27 mm) and right external iliac
splenic artery (21 mm) in the same 45-year-old woman. (C) Head and neck:
iddle) fusiform aneurysm of the top of the basilar artery in a 26-year-old man;
Videos 1, 2, 3, and 4.Patie
iddle a
l abdo
artery
in left
n; (m
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Aneurysms-Osteoarthritis Syndrome July 31, 2012:397–403None of these aortic dissections occurred during the 23
pregnancies and deliveries in our AOS cohort. In 1
patient, a dissection in a nondilated proximal left anterior
descending coronary artery was found.
Elective cardiovascular operations and interventions.
Fifteen patients underwent 1 or more elective cardiovascular
interventions at a mean age of 41  11 years: 12 valve-
paring aortic root replacements, 1 Bentall procedure, 2
plenic artery coiling procedures, and 1 abdominal aneurysm
epair; 1 patient underwent aortic repair surgeries in thorax
nd abdomen and mitral valve repair. In 2 patients, post-
perative complications occurred: 1 patient had painful
plenic ischemia for which reoperation was necessary and
nother patient had a total atrioventricular block after
alve-sparing aortic root replacement, for which pacemaker
mplantation was necessary.
neurysms and tortuosity of brachiocephalic and intra-
ranial vasculature. CTA of the brachiocephalic and in-
racranial vasculature was performed in 16 patients with a
ean age of 37  14 years. In 56% (9 of 16), we found
Outcome MeasurementsTable 2 Outco e Measurements
Covariates AOS Patients
Electrocardiography (n  31)
Heart rate, beats/min 67 12 (50–90)
PR interval, ms 159 24 (136–204)
QRS duration, ms 101 10 (90–118)
Echocardiography (n  31)
Left atrial diameter, mm 37 5 (26–49)
Interventricular septal thickness, mm 10 2 (9–15)
Left ventricular posterior wall thickness, mm 10 2 (8–14)
Left ventricular wall mass, g 204 75 (135–342)
Left ventricular end-diastolic diameter, mm 52 8 (40–64)
Left ventricular end-systolic diameter, mm 33 5 (25–42)
Fractional shortening, % 36 7 (28–48)
Peak E velocity, m/s 0.6 0.2 (0.3–0.9)
Peak A velocity, m/s 0.5 0.1 (0.3–0.7)
Transmitral E/A ratio 1.5 0.5 (0.5–2.2)
E-wave deceleration time, ms 233 82 (134–420)
Aortic diameters, mm
Annulus 26.8 3.1 (20–31)
Sinus of Valsalva 40.1 8.2 (30–50)
Sinotubular junction 31.9 4.8 (27–38)
Proximal ascending aorta 32.8 4.5 (27–46)
Computed tomography angiography (n  38)
Aortic diameters, mm
Annulus 29.8 5.9 (23–38)
Sinus of Valsalva 41.4 8.2 (30–63)
Sinotubular junction 32.0 4.9 (27–38)
Ascending thoracic aorta 32.4 5.2 (28–39)
Aortic arch 25.6 5.4 (19–34)
Descending thoracic aorta 24.9 4.5 (20–32)
Diaphragmatic level aorta 22.2 5.0 (16–28)
Abdominal aorta 22.3 5.3 (15–100)
Values are mean  SD (absolute range).
E/A  early/late atrial velocity; Other abbreviation as in Table 1.erebrovascular abnormalities (detailed information innline Table 2). Six patients (38%) were diagnosed with 1 or
ore intracranial aneurysms (Fig. 1C, Online Figs. 5 and 6).
ortuosity of brachiocephalic and intracranial vessels was
ound in 50% (8 of 16) of the patients (Fig. 1C, Online
ideo 4, Online Fig. 7). Thirty-one percent of patients (5 of
6) had a combination of aneurysms and tortuosity. In
ddition, 1 patient showed multiple caliber changes of both
ntracranial and extracranial vessels. In 7 patients, no cere-
rovascular abnormalities were found. Two patients were
eported to have had a nonfatal stroke at 56 and 76 years of
ge, respectively, but it is unclear from their medical
istories whether these were ischemic or hemorrhagic
trokes.
ardiac abnormalities. In 18 (51%) of 35 patients, 1 or
ore mitral valve abnormalities were diagnosed (5 prolapse;
billowing; and 5 mild, 2 moderate, and 3 severe cases of
itral valve regurgitation). In 2 patients, structural congen-
tal heart defects were found: 1 patient had an atrial septal
efect and persistent ductus arteriosus and another patient
ad mild congenital pulmonary valve stenosis (peak velocity:
.82 m/s) and persistent ductus arteriosus. A remarkable
nding in this patient was a saccular aneurysm within the
ersistent ductus arteriosus (7). In addition, 1 patient was
ound to have a bicuspid aortic valve during surgery.
Left ventricular systolic function and mitral inflow pat-
erns were normal in all patients (Table 2). Left ventricular
ypertrophy was present in 19% (6 of 31), with a mean
nterventricular septal thickness of 12  2 mm, a mean left
entricular posterior wall thickness of 12  2 mm, a mean
eft ventricular mass of 296  84 g, and mean body surface
rea-indexed left ventricular mass of 146  34 g/m2. None
of these patients had hypertension, aortic coarctation, or
aortic stenosis.
Rhythm disturbances. Electrocardiography revealed sinus
rhythm in all patients (Table 2). In 5 patients, premature
ventricular contractions (3) were found. Seven (22%) of 31
patients had a history of at least 1 episode of documented
atrial fibrillation (AF).
Aortic stiffness and biochemical measurements. Online
Table 3 shows aortic stiffness and biochemical measure-
ments for healthy controls and AOS patients. The aortic
pulse wave velocity (aPWV) tended to be higher in AOS
patients compared with controls (9.2  2.2 m/s vs. 7.8 
1.8 m/s, p  0.076). Compared with reference values
controlled for age and blood pressure, 6 (33%) of 18 patients
had an aPWV value of more than 2 SDs (8). Aortic
diameter and aPWV were not correlated (r  0.278, p 
0.357). N-terminal brain natriuretic peptide (NT-proBNP)
was higher in AOS patients than in matched controls (94.1
pg/ml, range: 52.5 to 172.9 pg/ml vs. 12.7 pg/ml, range: 8.5
to 55.1 pg/ml, p  0.001) and correlated with aPWV (r 
0.731, p  0.005).
Associated findings of AOS. Osteoarthritis was con-
firmed by x-rays in 25 (96%) of 26 patients who underwent
orthopedic evaluation, whereas 85% exhibited painful joints.
Mean age at osteoarthritis diagnosis was 42 years, whereas
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July 31, 2012:397–403 Aneurysms-Osteoarthritis Syndromethe youngest patient was 12 years of age. Spine, hands or
wrists, and knees most often were affected (detailed infor-
mation in Online Table 1). Pes planus was present in 91%
of patients and scoliosis was present in 61%. Other associ-
ated anomalies included hypertelorism (31%); abnormal
palate (54%); abnormal uvula (52%); hernia inguinalis or
umbilicalis (43%); and uterus, bladder, or bowel prolapse
(41%). More detailed information about these associated
findings will be reported separately (9).
Discussion
AOS is a recently described autosomal dominant connective
tissue disorder characterized by aneurysms, dissections, and
tortuosity throughout the arterial tree in combination with
osteoarthritis and mild craniofacial features. The AOS
phenotype may resemble that of other connective tissue
disorders such as MFS and LDS (Online Table 4). The
main site of aortic aneurysms in AOS is the sinus of
Valsalva. Similar to LDS, AOS is an aggressive disease with
substantial mortality and a high risk of aortic rupture and
dissection in mildly dilated aortas (10). AOS and LDS both
are associated with widespread arterial tortuosity and aneu-
rysms in the thorax and abdomen (10). In contrast to MFS,
cerebrovascular abnormalities frequently occur in AOS and
LDS (11). Identification of the underlying genetic defect in
TAAD patients is crucial, considering the variability in
prognosis, treatment strategy, and risk assessment in family
members.
Cardiac abnormalities in AOS. In addition to the aneu-
rysms and tortuosity of the arterial tree, we also found
cardiac abnormalities. A remarkable finding in approxi-
mately one fifth of the patients was left ventricular hyper-
trophy in the absence of hypertension or aortic stenosis.
Primary cardiomyopathy is reported in one quarter of MFS
patients showing mainly a reduced left ventricular ejection
fraction, but only in a minority (2.9%) was LV mass
increased (12). Mice studies have determined that TGF-
induces proliferation of cardiac fibroblasts and hypertrophic
growth of cardiomyocytes (13). Furthermore, TGF- neu-
tralizing antibodies were able to attenuate LV hypertrophy,
and losartan reduced nonmyocyte proliferation, implying
possible therapeutic implications in humans as well (14).
Similar to MFS, mitral valve abnormalities were common
in AOS patients, and 22% of AOS patients had a history of
AF. Mice studies have shown that TGF-1–induced myo-
ardial fibrosis in the atria plays an important role in
redisposing individuals to AF (15). Atrial fibrogenesis in
atients with AF occurs in 2 phases: an early increase, but
ater loss of responsiveness to TGF-1, while the fibrosis
progresses (16).
Furthermore, evidence from mouse studies suggests that
TGF- signaling is essential in the embryogenesis of the
eart, valvular pathogenesis, and organization of the aortic
all (17,18). In many mouse models with disrupted TGF-signaling activities, congenital heart defects are present (17). aIn the future, SMAD3 knockdown mice will help to explore
the mechanism behind the cardiac abnormalities in AOS.
Aortic stiffness and NT-proBNP in AOS. NT-proBNP
in AOS patients was elevated compared with that in
controls, although none of the patients had extremely high
NT-proBNP levels of more than 250 pg/ml. In vivo and in
vitro studies have shown that treatment with brain natri-
uretic peptide can attenuate cardiac hypertrophy via the
TGF-1 pathway (19). One may hypothesize that the
elevated NT-proBNP levels in AOS patients in fact are a
protective mechanism against the emergence of LV hypertro-
phy. Because (mildly to moderately) elevated NT-proBNP
levels in other patient groups are reported to predict
cardiovascular outcome and AF recurrence, evaluation of
the prognostic value of NT-proBNP in AOS patients with
respect to clinical outcome may be important (20,21).
The aPWV as a measure of aortic stiffness was high-
normal in AOS patients, as was described previously in, for
instance, patients with MFS and bicuspid aortic valve
(22,23). Ascending aortic diameter and aPWV were not
correlated, suggesting that arterial stiffness occurs indepen-
dently of aneurysm formation. In MFS patients, an aug-
mentation index of more than 11% has been reported to
predict progression of aortic diameters, so further research is
warranted to test whether this also holds true for AOS
patients (24).
Clinical suggestions for cardiologists treating AOS
patients. Although AOS is a recently discovered aneurysm
syndrome and the full spectrum of the disease and its progres-
sion need to be clarified, some preliminary suggestions may be
derived from the current findings. Because multisystem in-
volvement frequently is observed, cooperation in a multidisci-
plinary team with clinical geneticists, cardiologists, orthopedic
surgeons, radiologists, neurologists, and, when necessary, (vas-
cular or cardiothoracic) surgeons is important.
MONITORING AND SCREENING. Cardiologists should sus-
ect AOS in every TAAD patient without molecular
iagnosis or known cause and should test these patients for
MAD3 mutations. Furthermore, we suggest that clinicians
reating patients with arterial aneurysmal disease in any
arge artery (intracranial, iliac, splenic artery, and so on)
hould at least ask whether these patients report joint
ymptoms. In the physical examination, one must pay
pecial attention to presence of AOS-associated findings,
uch as joint anomalies and abnormal uvula.
Extensive cardiovascular evaluation using echocardiography
nd CTA or magnetic resonance imaging (head to pelvis) is
ecommended in every adult AOS patient. Initially, these
iagnostic investigations should be performed annually to
etermine rate of progression. Thereafter, frequency of imag-
ng should be guided by the findings, for instance, annually if
he aortic diameter is more than 35 mm or if the aortic
iameter shows significant growth (5 mm/year).
The phenotype seems to be age-dependent, becauseneurysms mainly and dissections only occurred in adult-
A
m
t
A
b
i
l
c
m
t
t
a
s
(
p
p
l
a
i
t
a
i
S
i
b
h
b
t
r
i
C
A
c
t
d
m
A
i
s
w
r
1
1
1
1
402 van der Linde et al. JACC Vol. 60, No. 5, 2012
Aneurysms-Osteoarthritis Syndrome July 31, 2012:397–403hood; however, our series included only 6 children with
AOS. Concerning screening in childhood, clear suggestions
are difficult to formulate at this time. We suggest that
frequency of cardiologic evaluation with TTE, magnetic
resonance imaging, or both must be guided by the aortic
root z-score and presence of other cardiac abnormalities.
Although in our cohort no dissections occurred during
pregnancy or delivery, pregnancy should be considered high
risk in AOS patients with aneurysms, as in those with MFS
and LDS (25).
TREATMENT. The implication of TGF- signaling in the
pathogenesis of aortic aneurysm syndromes suggests a
TGF- antagonist as a specific pharmaceutical target (26).
lthough losartan showed promising results in MFS mouse
odels, we have to await the results of randomized clinical
rials in MFS, SMAD3 knockdown mice, and consequently
OS clinical trials (26). At the moment, attention should
e focused on genetic counseling, screening of relatives, and
nterventional or surgical treatment. Medical treatment with
osartan, beta-blockade, or both may be beneficial. Stringent
ontrol of hypertension to limit aortic wall stress is recom-
ended (27).
Because dissections in AOS patients can occur at rela-
ively small aortic diameters, early elective surgical interven-
ion is indicated to reduce the risk of mortality. Because data
re limited and the rate of progression is unknown, we
uggest applying the surgical recommendations for LDS
27). Valve-sparing aortic root replacement using the reim-
lantation technique is the intervention of choice (28). For
eripheral aneurysms, individual size or rate of growth and
ocation must determine the treatment strategy.
Currently, the risk of rupture of intracranial aneurysms
ssociated with AOS is unknown. No deaths resulting from
ntracranial hemorrhage occurred in our series. Life expec-
ancy and size, location, and rate of growth of the aneurysm
re the most important determinants to decide whether
ntervention is needed.
tudy limitations. First, the number of subjects included
n the present study is relatively small, because AOS has
een discovered only recently. Second, the population is quite
eterogeneous, particularly in disease severity and age, and
ecause of logistical reasons and mortality, it was not possible
o perform every examination in all 44 patients. Further
esearch is necessary to confirm our findings and to gain more
nsight in the disease mechanism and progression.
onclusions
OS is an aggressive, inherited, connective tissue disorder
haracterized by arterial tortuosity, aneurysms, and osteoar-
hritis. Aortic root enlargement is the most common car-
iovascular finding in our series, but cerebrovascular abnor-
alities were also present in more than 50% of patients.
ortic dissections occur at smaller diameters than observed
n, for instance, MFS, and as such need early elective
urgical treatment. Larger prospective follow-up studies are
1arranted to determine progression over time and clinical
elevancy of the cardiac and intracranial abnormalities.
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APPENDIX
For an expanded Methods section and for supplementary figures,
videos, and tables, please see the online version of this article.
